+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
FEMALE
ID06548919

Observing Safety and Effectiveness of Treatments for Women with ESR1-mutated HRHER2- Advanced Breast Cancer After Endocrine Therapy

Led by SciClone Pharmaceuticals · Updated on 2024-08-12

450

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are observing the effectiveness and safety of different treatment plans in women with ESR1-mutated hormone receptor-positive, HER2-negative advanced breast cancer who have not responded to prior endocrine therapy. This prospective, non-interventional real-world study aims to collect detailed data on how these patients respond to treatments over time, providing important information about outcomes in a clinical setting. Participants will receive various treatment regimens, including endocrine therapies such as tamoxifen, aromatase inhibitors, and fulvestrant, or chemotherapy treatments approved for advanced breast cancer. The study will track each subjects treatment and health status without assigning specific interventions, reflecting routine clinical practice. During the study, researchers will collect data on treatment efficacy and safety every 2 to 3 months until disease progression, new treatments, death, or loss to follow-up. Safety assessments continue for 4 weeks after stopping treatments. The primary outcome measured is progression-free survival over 18 months, with secondary outcomes including response rates and duration of response. Participants will be involved in regular assessments and monitoring throughout the study period.

CONDITIONS

Brief Title

Current Status of Treatment for Chinese Patients With ESR1-mutated HR+/HER2-advanced Breast Cancer

Research Team

C

Chunyang Li

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here